Search

1 to 10 of 81
Sort by

Library Entry
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

Immune effector cell (IEC) therapies offer durable and sustained remissions in significant numbers of patients with hematological cancers. While these unique immunotherapies have improved outcomes for pediatric and adult patients in a number of disease states, as ‘living drugs,’ their toxicity...


Library Entry
Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee

Immunotherapy is now a cornerstone for cancer treatment, and much attention has been placed on the identification of prognostic and predictive biomarkers. The success of biomarker development is dependent on accurate and timely collection of biospecimens and high-quality processing, storage and...


Library Entry
Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I—conceptual challenges

The sharing of clinical trial data and biomarker data sets among the scientific community, whether the data originates from pharmaceutical companies or academic institutions, is of critical importance to enable the development of new and improved cancer immunotherapy modalities. Through data...



Library Entry
SITC Clinical Practice Guidelines: Acute Leukemia - Recorded Webinar and Presentation Slides

On January 11, 2021, leading experts in cancer immunotherapy presented an overview of the recently published "The Society for Immunotherapy of Cancer (SITC) Clinical Practice Guideline on Immunotherapy for the Treatment of Acute Leukemia" during a live webinar. Webinar Faculty: ...

2 attachments


Library Entry
SITC Cancer Immunotherapy Guidelines - Multiple Myeloma - Recorded Webinar and Presentation Slides

On September 3, 2020, leading experts in cancer immunotherapy presented an overview of the publication "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma" during a live webinar. The recorded webinar and presentation slides are...

2 attachments




Library Entry
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation

The interaction between the immune system and tumor cells is an important feature for the prognosis and treatment of cancer. Multiplex immunohistochemistry (mIHC) and multiplex immunofluorescence (mIF) analyses are emerging technologies that can be used to help quantify immune cell subsets,...